12,585 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Entropy Technologies LP

Entropy Technologies LP purchased a new position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,585 shares of the medical equipment provider's stock, valued at approximately $1,025,000.

Several other hedge funds and other institutional investors have also made changes to their positions in HOLX. Cetera Investment Advisers increased its position in shares of Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider's stock worth $1,595,000 after acquiring an additional 13,380 shares in the last quarter. Clearbridge Investments LLC increased its stake in Hologic by 51.4% during the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider's stock valued at $40,430,000 after purchasing an additional 176,006 shares during the last quarter. Andra AP fonden raised its stake in Hologic by 224.5% during the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider's stock worth $7,083,000 after acquiring an additional 66,000 shares during the period. Swedbank AB lifted its holdings in shares of Hologic by 5.2% in the 2nd quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider's stock worth $121,060,000 after purchasing an additional 80,575 shares during the last quarter. Finally, National Bank of Canada FI boosted its holdings in shares of Hologic by 352.0% during the first quarter. National Bank of Canada FI now owns 299,098 shares of the medical equipment provider's stock valued at $22,474,000 after acquiring an additional 232,928 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on HOLX shares. Evercore ISI boosted their price target on shares of Hologic from $78.00 to $82.00 and gave the stock an "in-line" rating in a research report on Tuesday, October 1st. StockNews.com raised shares of Hologic from a "hold" rating to a "buy" rating in a research report on Thursday. Leerink Partners reduced their price target on shares of Hologic from $95.00 to $90.00 and set an "outperform" rating for the company in a research report on Tuesday, October 8th. Royal Bank of Canada lifted their price objective on Hologic from $86.00 to $89.00 and gave the company a "sector perform" rating in a research report on Tuesday, November 5th. Finally, Raymond James increased their price target on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $89.91.

Hologic Stock Down 2.1 %

NASDAQ:HOLX traded down $1.64 on Thursday, hitting $77.54. 1,657,173 shares of the company's stock were exchanged, compared to its average volume of 1,592,855. The firm has a 50-day moving average price of $80.77 and a 200-day moving average price of $78.22. Hologic, Inc. has a 52 week low of $67.59 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The company has a market cap of $18.01 billion, a P/E ratio of 23.29, a price-to-earnings-growth ratio of 2.52 and a beta of 0.98.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million for the quarter, compared to analysts' expectations of $978.25 million. During the same quarter in the prior year, the business earned $0.89 EPS. The firm's revenue for the quarter was up 4.5% on a year-over-year basis. As a group, analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.